Drug updated on 3/28/2024
| Dosage Form | Injection (intravenous; 1 mg/kg, 1.5 mg/kg) |
| Drug Class | Tetracycline class antibacterials |
| Ongoing and Completed Studies | ClinicalTrials.gov |
Indication
- For treatment of complicated intra-abdominal infections in adults ≥18 years of age.
Summary
- Eravacycline (Xerava) is indicated for the treatment of complicated intra-abdominal infections in adults aged 18 years and above.
- A total of seven systematic reviews/meta-analyses were reviewed, which compared eravacycline's clinical efficacy and safety to other antibiotics such as carbapenems, tigecycline, meropenem, ertapenem, ceftazidime/avibactam+metronidazole among others.
- The studies found that eravacycline had similar clinical cure rates at test-of-cure visits when compared with other antibiotics across different populations including modified intent-to-treat population, microbiologically evaluable population and clinically evaluable population.
- In terms of microbiological response rate at end of treatment for acute bacterial infections, one study showed that eravacycline was significantly better than tigecycline but not significantly different from six other regimens used in China.
- While some studies reported higher risk of adverse events like nausea with eravacycline use compared to comparators like carbapenems or cefepime plus metronidazole; serious adverse events or discontinuation due to these events did not differ significantly between groups treated with either drug regimen.
- Despite its comparable effectiveness against multidrug-resistant Acinetobacter baumannii infection relative to older drugs according to a review paper on recent literature about this pathogen's management options; more randomized controlled trials are needed before novel agents like cefiderocol or plazomicin can be recommended over existing treatments such as Xerava (Eravacyline).
Product Monograph / Prescribing Information
| Document Title | Year | Source |
|---|---|---|
| Xerava (eravacycline) Prescribing Information. | 2021 | Tetraphase Pharmaceuticals Inc, Watertown, MA |